The promise and peril of KRAS G12C inhibitors
- PMID: 34375610
- DOI: 10.1016/j.ccell.2021.07.011
The promise and peril of KRAS G12C inhibitors
Abstract
RAS mutant tumors have been largely refractory to therapies until now. Recent findings published in the New England Journal of Medicine show that sotorasib provides clinical benefit for KRAS p.G12C-mutated non-small-cell lung cancer (NSCLC) and provide mechanistic insights into acquired resistance to KRASG12C-specific inhibition.
Copyright © 2021 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests S.M. is an employee and stockholder of Genentech/Roche. A.R.M. is a post-doctoral fellow employed by Genentech/Roche.
Comment on
-
Acquired Resistance to KRASG12C Inhibition in Cancer.N Engl J Med. 2021 Jun 24;384(25):2382-2393. doi: 10.1056/NEJMoa2105281. N Engl J Med. 2021. PMID: 34161704 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous